OpenAI Halts GPT-6.1 Astra Release Over Safety Failures

Anthropic claims AI found Crispr-like enzyme

Anthropic’s Claude identified a novel reverse transcriptase system in jumbo phages that resembles CRISPR, but the scientific community remains skeptical. While the speed of discovery is impressive, experts note the finding lacks wet-lab validation and may simply be pattern recognition on known data. The real story isn't a new gene-editing tool, but the opaque nature of how an AI model sifts through genomic databases to propose hypotheses that humans must still verify.

OpenAI delays GPT-6.1 Astra over safety risks

OpenAI has paused the release of GPT-6.1 Astra, citing significant safety concerns that outweigh its performance gains. This decision underscores a growing tension in the industry: as models become more capable, they also become harder to constrain within safe operational boundaries. While Anthropic pushes forward with Claude Sonnet 5.5 and reports massive financial losses ahead of an IPO, OpenAI is choosing caution over speed. The delay signals that safety evaluations are becoming a primary bottleneck for next-generation model releases, potentially shifting the competitive landscape toward more conservative development cycles. By halting Astra, OpenAI acknowledges that raw capability alone no longer guarantees a viable product launch. This move forces competitors to reconsider their own release timelines and safety protocols. The industry now watches closely to see if this caution becomes the new standard for frontier AI development.